Twist Bioscience Corp is seeing a significant rise in its stock price, reflecting positive market sentiment.
Twist Bioscience Corp (NASDAQ:TWST) is up today, with shares increasing by 2.82% to close at CA$198.68. This rise follows recent developments in the biotechnology sector, especially related to its collaborations and advancements in AI-driven drug discovery.
Advertisement
Twist Bioscience Corp
TWST.US
TWST.US
Twist Bioscience Corp
WealthAwesomeMarket cap
$12.81B
52W high
$197.19
52W low
$23.30
1W change
+21.92%
Beta
2.22
Analyst Price Targets
Based on 12 analysts covering TWST · as of Oct 1, 2026
Wall Street analysts forecast TWST stock price to fall 42.0% over the next 12 months.
Consensus
Buy4.17 / 5.00
Avg. Target
C$112.08
-42.0% Upside
Previously C$109.58 on Sep 21, 2026
Current Price
C$193.24
Last close
Analyst Breakdown (12 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TWST's historical volatility
30-Day Vol
94.2%
Annualized
90-Day Vol
85.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$231.02
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$205.09 | C$148.20 – C$283.82 |
| 60 trading days | C$217.67 | C$137.49 – C$344.61 |
| 90 trading days | C$231.02 | C$131.61 – C$405.53 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are optimistic about the company's strategic partnerships and its focus on innovative solutions in biotechnology, which may boost its long-term growth potential.
Market Cap Reaches $12.81 Billion
Twist Bioscience's market capitalization has reached about $12.81 billion, showing strong investor interest in its innovative technologies.
Bull case
The recent partnership with Eli Lilly to enhance AI drug discovery capabilities positions Twist Bioscience as a significant player in the fast-evolving biotech landscape. This collaboration could lead to substantial revenue growth.
Bear case
Despite the positive momentum, there are concerns about profitability. Twist Bioscience has not yet achieved a positive profit margin, which might impact investor confidence over time.
Advertisement
Strategic Partnerships Fuel Growth
Twist Bioscience's collaboration with Eli Lilly to improve AI-driven drug discovery has attracted attention. This partnership aims to use advanced technologies to streamline the drug development process, potentially positioning the company for significant growth in the competitive biotech market.
Market Sentiment and Future Prospects
The positive movement in Twist Bioscience's stock reflects a broader optimism in the biotechnology sector. Investors are increasingly seeking companies that can innovate and adapt to the changing landscape, and Twist's focus on AI applications in drug discovery aligns well with these trends.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
